Online inquiry

IVTScrip™ mRNA-Human ATAD2B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK23337MR)

This product GTTS-WK23337MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ATAD2B protein. This product can be used in Meiotic prophase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001242338.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 54454
UniProt ID Q9ULI0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ATAD2B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK23337MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WK23938MR IVTScrip™ mRNA-Human ATAD3A, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ATAD3A
GTTS-WK28215MR IVTScrip™ mRNA-Human APOA1BP, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APOA1BP
GTTS-WK19892MR IVTScrip™ mRNA-Human Aldehyde Dehydrogenase 1-A1, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Aldehyde Dehydrogenase 1-A1
GTTS-WK21397MR IVTScrip™ mRNA-Human ALDH1L1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALDH1L1
GTTS-WK14013MR IVTScrip™ mRNA-Human ADARB1, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADARB1
GTTS-WK12020MR IVTScrip™ mRNA-Human AARSD1, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AARSD1
GTTS-WK4155MR IVTScrip™ mRNA-Human CD45RA, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD45RA
GTTS-WK18387MR IVTScrip™ mRNA-Human ALAS1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALAS1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW